fbpx

Researchers Honoured at Cancer Institute NSW Awards

ACRF, Australian Cancer Research Foundation, Cancer Research, Cancer Research Grants, cancer scientists, current cancer research, Fighting cancer, Garvan Institute of Medical Research, Cancer Institute NSW, Cancer Institute MSW Awards, Sydney Children’s Hospital Network, Premier’s Awards for Outstanding Cancer Research, Dr Geffrey McCowage, Amber Johns, Professor Terry Speed

Last Friday the ACRF attended the 2015 Premier’s Awards for Outstanding Cancer Research. These awards honour the achievements of the individuals and teams that work across the cancer research sector to lessen the impact of cancer on the community through prevention, early detection, innovation, and research discoveries.

The event marked the 10th anniversary of the awards and was hosted by the Cancer Institute NSW at Doltone House, Hyde Park. Over three hundred guests from the health and medical sector attended.

The night celebrated excellence and innovation in cancer research, acknowledging the immense contributions of professionals who have dedicated their life’s work to improving the lives of people with cancer, and commending ‘rising stars’ who are embarking on brilliant new research endeavours.

Throughout the night, speeches not only discussed the scientific implications of their findings on future treatments and preventions, but recognised the real world difference cancer research is making to patients battling the disease today.

Keynote speaker Professor Terry Speed, a world-leader in statistics and bioinformatics, marvelled at the impact cancer research teams have on patients. “I severely underestimated the realism of the people in this room. It was a moment of awakening for me, when I realised that someone I knew from an institute that I worked at had made such an impact on my nephew who just had a stem cell transplant.”

Winner of the ‘Wildfire’ Highly Cited Publication Award, Ms Amber Johns, acknowledged the collaborative nature of cancer research worldwide, “it’s important to thank the dedicated scientists undertaking the research, the clinicians for everything they do for our patients and to our patients who volunteer for these studies, and allow researchers into their bedside at such a vulnerable time in their lives.”

Dr Geoffrey McCowage, a paediatric oncologist at the Sydney Children’s Hospital Network Westmead won the Excellence in Translation Cancer Research Award for his work with Gene Therapy. He shared insight on the emotional impact of working in this field. When asked whether the scientific rewards outweigh how difficult it is to work with childhood cancers, Dr McCowage responded with “Absolutely, however people often ask me if it gets any easier to deal with tragedy, and as the years go on I honestly have to say it gets harder.”

Despite the difficulties, Professor Speed revealed that in his experience he found that many researchers are motivated to continue on by a single thought: “There’s a driving force at the back of our minds – if a Eureka moment does happen, there will be an army of people who will bring this discovery from the bench to the bedside.”

The Australian Cancer Research Foundation thanks the nominees and award winners for their hard work and dedication. We know that these awards go beyond recognition of a scientists achievement, they are a celebration of the shared progress that brings us closer towards finding a cure for all cancers.

Professor Haber wins NSW Cancer Researcher of the Year

Prof-M-Haber-WebThe annual Cancer Institute NSW’s Premier’s Awards for Outstanding Cancer Research were awarded last Friday evening at Sydney Town Hall and we are extremely proud to announce that ACRF Medical Research Advisory Committee member Professor Michelle Haber AM has been awarded the Outstanding Cancer Researcher Award for 2014. 

This prestigious award honours an individual who has made significant and fundamental contributions to any field of cancer research in NSW, and comes with a prize of $50,000 to further the recipient’s research endeavours.

Professor Haber is the Executive Director of the Children’s Cancer Institute Australia, and has previously been awarded the Excellence in Translational Research Award at the Premier’s Awards in 2012. She is internationally recognised for her world-class research into the treatment of neuroblastoma and acute lymphoblastic leukaemia in children.

We are very proud to count Professor Haber as a member of the ACRF Medical Research Advisory Committee. Committee members are cancer scientists of the highest national and, in many cases, global repute.

They are leaders in Australian cancer research and advise the ACRF on applications received for ACRF grants funding, making recommendations to the Board of Trustees of ACRF as to where grants should be awarded for maximum impact and innovation in cancer prevention, diagnosis and cure.

Excellence in children’s cancer research was further recognised on the night with the Premier’s Rising Star Award and the Outstanding Cancer Research Fellow of the Year going to members of the Kids Cancer Alliance.

Associate Professor Georgina Long from the Melanoma Institute Australia was awarded the Wildfire Award, and collaborations working in haematological clinical research and asbestos research were also acknowledged for their efforts in their fields.

ACRF grant recipients receive NSW Premier's praise

Researchers from three ACRF-funded cancer research centres have received accolades at the 2012 NSW Premier’s Awards for outstanding cancer research.

Hosted by the Cancer Institute NSW, the awards honour the work of the State’s most innovative and dynamic cancer researchers, and so we congratulate these esteemed scientists:

1. Excellence in Translational Research
Professors Michelle Haber, Glenn Marshall, and Murray Norris – Children’s Cancer Institute Australia (CCIA) for Medical Research

This team from CCIA (a recipient of two ACRF grants totaling $3.6m) have been acknowledged for their ground-breaking work in testing children with Acute Lymphoblastic Leukaemia (ALL) and improving survival rates. Their minimal residual disease testing (MRD) can predict which children suffering ALL are at the highest risk of relapse on standard therapy, triggering individualised treatment to commence at earlier stages.

Continue reading “ACRF grant recipients receive NSW Premier's praise”